Picture of Apellis Pharmaceuticals logo

APLS — Apellis Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapNeutral

Momentum

Relative Strength (%)
1m-20.16%
3m+17.05%
6m-44.53%
1yr-40.28%
Volume Change (%)
10d/3m-41.88%
Price vs... (%)
52w High-47.38%
50d MA-11.67%
200d MA-21.28%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-96.73%
Return on Equity-2144.31%
Operating Margin-162.85%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Apellis Pharmaceuticals EPS forecast chart

Profile Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing novel therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
September 25th, 2009
Public Since
November 9th, 2017
No. of Shareholders
22
No. of Employees
486
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
95,969,000
Blurred out image of a map
Address
100 Fifth Avenue, WALTHAM, 02451
Web
http://apellis.com/
Phone
+1 6179775700
Auditors
Deloitte & Touche LLP

APLS Share Price Performance

Latest News for APLS

Upcoming Events for APLS

Q4 2021 Apellis Pharmaceuticals Inc Earnings Release

Q1 2022 Apellis Pharmaceuticals Inc Earnings Release

Apellis Pharmaceuticals Inc Annual Shareholders Meeting

Similar to APLS

Picture of Abcam logo

Abcam

us flag iconNASDAQ Global Select Market

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amryt Pharma logo

Amryt Pharma

us flag iconNASDAQ Global Select Market

Picture of Anika Therapeutics logo

Anika Therapeutics

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email